Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Maillard reaction inhibitors from Kissei

Dec. 3, 1997

MAbs to lymphocyte/endothelial adhesion molecules prevent diabetes in mouse model

Dec. 2, 1997

Muse approved in U.K.

Dec. 2, 1997

Further labeling changes for Rezulin/Noscal; Romozin availability suspended in U.K.

Dec. 2, 1997

AHP describes new compounds with tissue-selective estrogenic and antiestrogenic effects

Dec. 1, 1997

Sankyo discloses agents for diabetes and related complications

Nov. 28, 1997

Lilly prepares new benzothiophenes

Nov. 28, 1997

New approvals for Menorest

Nov. 28, 1997

Negative phase II results for long-term risedronate in osteoporosis

Nov. 28, 1997

Launch of Ligand/Lilly metabolic disease alliance

Nov. 27, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...